Study Comparing Intrathecal Morphine and TAP Block with Ropivacaine and Clonidine for Pain Relief in Patients Undergoing Elective Cesarean Section
- Participants:Adults
Rare diseases
Investigational molecules
Locations
Morphine hydrochloride trihydrate is a strong pain medicine belonging to the opioid class of drugs. It is a chemically synthesised substance, classified as morphine with the ATC code N02AA01.[2] In the registry data it appears under the product name Morphine Unimedic 1 mg/ml injektionsvätska, lösning, and it is authorised as a medicine in Sweden.[1] The substance is the hydrochloride trihydrate salt form of morphine, an opioid that has been used in medicine for many decades. It is listed as a controlled drug in some countries because of its potential for dependence and misuse.[3]
Morphine works by attaching to opioid receptors in the brain and spinal cord. These receptors are part of the body's natural pain-control system. When morphine binds to them, it changes the way pain signals are transmitted and perceived, reducing the sensation of pain. The trials listed here use morphine injected directly into the fluid surrounding the spinal cord, a route that places the medicine close to these receptors. The supplementary sources describe morphine sulfate, a related salt form, as an opioid agonist that can cause serious side effects including respiratory depression, meaning slowed or stopped breathing.[3]
In the clinical trials listed, morphine hydrochloride trihydrate is given as a solution for injection by the intrathecal route, meaning it is injected into the fluid around the spinal cord.[2][1] The registry records describe the pharmaceutical form as a solution for injection. The supplementary sources also describe morphine sulfate in oral forms, including extended-release tablets and an oral solution, but these are different salt forms and routes from the intrathecal product used in the trials.[3][4]
Two Phase 3 trials are listed for morphine hydrochloride trihydrate, both authorised and interventional. The first trial, NCT07377630, is a pilot randomised controlled trial in 100 participants having elective caesarean section under spinal anaesthesia. It compares a low dose of intrathecal morphine with a TAP block using ropivacaine and clonidine. The primary endpoint is how many times the somatic pain score at rest reaches 6 or more on a visual analogue scale at several time points up to 24 hours after spinal anaesthesia.[2]
The second trial, 2024-520262-58-01, involves 124 participants having open colorectal surgery with a midline incision. It compares intrathecal morphine with thoracic epidural analgesia. The primary outcome is the mean Quality of Recovery-15 Swedish version score on postoperative day 2, adjusted for the preoperative score, with a minimally clinically important difference between groups set at 8.[1]
Both trials measure pain and recovery after surgery. The caesarean section trial focuses on pain scores at rest, while the colorectal surgery trial focuses on patient-reported quality of recovery. The participant populations are adults having planned surgery. The trials are authorised, meaning they have received regulatory approval to proceed. No results are yet reported in the registry data.
The supplementary sources describe side effects of morphine sulfate, a closely related salt form of morphine. Common side effects include constipation, nausea, and drowsiness.[3] Serious side effects include addiction, abuse, and misuse, which can lead to overdose and death. Life-threatening respiratory depression, meaning dangerously slowed or stopped breathing, may occur, especially when starting treatment or increasing the dose.[3] Neonatal opioid withdrawal syndrome can occur in newborns exposed to morphine during pregnancy.[3] The sources do not report side effects specific to the intrathecal hydrochloride trihydrate form used in the trials.
Each condition opens its own overview and trial list
Recruiting trials first
Tell us about your condition – we search every trial in Europe and connect you with the right site.